286 related articles for article (PubMed ID: 28734696)
1.
Sato J; Kitagawa Y; Watanabe S; Asaka T; Ohga N; Hirata K; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Sep; 124(3):261-270. PubMed ID: 28734696
[TBL] [Abstract][Full Text] [Related]
2. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic volume evaluated by
Sato J; Kitagawa Y; Watanabe S; Asaka T; Ohga N; Hirata K; Shiga T; Satoh A; Tamaki N
Int J Oral Maxillofac Surg; 2018 May; 47(5):553-560. PubMed ID: 29030021
[TBL] [Abstract][Full Text] [Related]
4. Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.
Sato J; Kitagawa Y; Yamazaki Y; Hata H; Asaka T; Miyakoshi M; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2031-41. PubMed ID: 24867258
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
[TBL] [Abstract][Full Text] [Related]
6. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
[TBL] [Abstract][Full Text] [Related]
7. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
8. [18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma.
Shimomura H; Sasahira T; Yamanaka Y; Kurihara M; Imai Y; Tamaki S; Yamakawa N; Shirone N; Hasegawa M; Kuniyasu H; Kirita T
Int J Clin Oncol; 2015 Apr; 20(2):308-16. PubMed ID: 24942501
[TBL] [Abstract][Full Text] [Related]
9. SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma.
Miyawaki A; Ikeda R; Hijioka H; Ishida T; Ushiyama M; Nozoe E; Nakamura N
Oncol Rep; 2010 May; 23(5):1205-12. PubMed ID: 20372831
[TBL] [Abstract][Full Text] [Related]
10. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
[TBL] [Abstract][Full Text] [Related]
11. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
12. Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.
Kawai N; Lin W; Cao WD; Ogawa D; Miyake K; Haba R; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1870-8. PubMed ID: 24781871
[TBL] [Abstract][Full Text] [Related]
13. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
[TBL] [Abstract][Full Text] [Related]
14.
Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
[TBL] [Abstract][Full Text] [Related]
15. Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas.
Yamada T; Uchida M; Kwang-Lee K; Kitamura N; Yoshimura T; Sasabe E; Yamamoto T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Apr; 113(4):464-71. PubMed ID: 22676927
[TBL] [Abstract][Full Text] [Related]
16. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis.
Bekaert L; Valable S; Lechapt-Zalcman E; Ponte K; Collet S; Constans JM; Levallet G; Bordji K; Petit E; Branger P; Emery E; Manrique A; Barré L; Bernaudin M; Guillamo JS
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1383-1392. PubMed ID: 28315948
[TBL] [Abstract][Full Text] [Related]
17. Assessment of biological parameters in head and neck cancer based on in vivo distribution of
Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W
Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858
[TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with ¹⁸F-FDG PET and immunohistochemistry.
Miyashita G; Higuchi T; Oriuchi N; Arisaka Y; Hanaoka H; Tominaga H; Morita S; Miyakubo M; Ishikita T; Nakasone Y; Negishi A; Yokoo S; Endo K
Ann Nucl Med; 2010 Oct; 24(8):579-84. PubMed ID: 20652456
[TBL] [Abstract][Full Text] [Related]
19. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745
[TBL] [Abstract][Full Text] [Related]
20. The optimal
Gertsenshteyn I; Epel B; Ahluwalia A; Kim H; Fan X; Barth E; Zamora M; Markiewicz E; Tsai HM; Sundramoorthy S; Leoni L; Lukens J; Bhuiyan M; Freifelder R; Kucharski A; Giurcanu M; Roman BB; Karczmar G; Kao CM; Halpern H; Chen CT
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4014-4024. PubMed ID: 35792927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
